shopping cart Your cart is empty
  • Home
  • Press Release
  • Companion Diagnostics Market Has Been Expected To Grow With A CAGR Of 23.2% During The Forecast Period Of 2016-2022

Companion Diagnostics Market Has Been Expected To Grow With A CAGR Of 23.2% During The Forecast Period Of 2016-2022

Jul 29, 2016

According to a recently published report, the global Companion Diagnostics Market has been expected to grow with an impressive double digit CAGR of 23.2% during 2016-2022. The global companion diagnostics market is segmented on the basis of application, technology, end user,and geography. The report on global companion diagnostics market forecast 2016-2022 (by application, technology, end user,and geography) provides a detailed overview and predictive analysis of the market.


Full report is available onglobal companion diagnostics market forecast2016-2022 (by application, technology, end user, and geography)report at http://www.briskinsights.com/report/companion-diagnostics-market


According to the FDA,the companion diagnostic is a medical device,often an in vitro device, which provides information that is essential for the safe and effective use of a corresponding drug or biological product. The test helps a health care professional determine whether a particular therapeutic product’s benefits to patients will outweigh any potential serious side effects or risks. Due to the technological advancements, the market of companion diagnostic is growing rapidly, which is the major driver steering the growth of the market. The growing prevalence of diseases like HIV and cancer are propelling the companion diagnostic market, as they help in deciding the specific dosage of drugs for the patients. About the drugs toxicities, awareness among the patients and physicians is helping the market to grow. But, the costs involved in the research and development of the drugs is very high, which isbecoming a major restraint for the companion diagnostics market.Lack of awareness among the patients and government policies and regulation are the major challengesfacing the market.


Scope of the Report

1. Global Companion Diagnostics Market by Application 2012-2022 ($ Million)
1.1. Colorectal Cancer
1.2. Breast Cancer
1.3. Lung Cancer
1.4. Melanoma
1.5. Urology
1.6. Gastric Cancer

2. Global Companion Diagnostics Market by Technology 2012-2022 ($ Million)
2.1. Polymerase Chain Reaction (PCR)
2.2. In Situ Hybridization (ISH)
2.3. Immunohistochemistry (IHC)
2.4. Other Technologies (NGS,Multiplex Assay, Cellular Immune Testing, Mab)

3. Global Companion Diagnostics Market by End User 2012-2022 ($ Million)
3.1. Pharmaceutical Companies
3.2. Reference Lab
3.3. Others (CRO, Physicians, Hospitals & Academic Medical Centers)

4. Global Companion Diagnostics Market Regional Outlook 2012-2022($Million)
4.1. North America
4.2. Europe
4.3. Asia Pacific
4.4. Middle East & Africa
4.5. Latin America

5. Company Profiles
5.1. Abbott Laboratories, Inc
5.2. Biomerieux
5.3. Dako (Agilent Technologies)
5.4. Leica Microsystems
5.5. Life Technologies.
5.6. Myriad Genetics, Inc.
5.7. Qiagen
5.8. Resonance Health Ltd.
5.9. Roche
5.10. Ventana Medical Systems
5.11. Agilent Technologies, Inc.
5.12. BioGenex Laboratories
5.13. Danaher Corporation
5.14. Ge Healthcare
5.15. Thermo Fisher Scientific, Inc.